Sai Life Sciences (NSE:SAILIFE) Marketable Securities: ₹1,799 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SAILIFE Sai Life Sciences Ltd NSE:SAILIFE
18 GF Score
Price ₹1,315.10
! 5 Warning Signs
View Full Analysis

What is Sai Life Sciences Marketable Securities?

Sai Life Sciences NSE:SAILIFE -0.01% 18 Marketable Securities is ₹1,799 Mil as of Mar. 2026. GuruFocus rates NSE:SAILIFE with a GF Score™ of 18/100. The stock has 5 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Sai Life Sciences's Marketable Securities for the quarter that ended in Mar. 2026 was ₹1,799 Mil.

Sai Life Sciences's annual Marketable Securities increased from Mar. 2024 (₹1,610 Mil) to Mar. 2025 (₹2,811 Mil) but then declined from Mar. 2025 (₹2,811 Mil) to Mar. 2026 (₹1,799 Mil).

Sai Life Sciences  (NSE:SAILIFE) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Sai Life Sciences Marketable Securities Related Terms

Sai Life Sciences Marketable Securities Historical Data

* Premium members only.

The historical data trend for Sai Life Sciences's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sai Life Sciences Marketable Securities Chart

Sai Life Sciences Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
Marketable Securities
1,000.00 1,350.00 1,610.00 2,811.33 1,799.20

Sai Life Sciences Quarterly Data
Mar22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,811.33 0.00 1,581.42 0.00 1,799.20
NSE:SAILIFE
18GF Score
Sai Life Sciences Ltd NSE:SAILIFE
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sai Life Sciences Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of ₹1,799 Mil mean?
Sai Life Sciences (NSE:SAILIFE) has a Marketable Securities of ₹1,799 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Sai Life Sciences and its competitors.
Is Sai Life Sciences' Marketable Securities too high?
Sai Life Sciences' current Marketable Securities is ₹1,799 Mil. Overall, Sai Life Sciences has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Sai Life Sciences' Marketable Securities compare to TMO and DHR?
Sai Life Sciences' Marketable Securities of ₹1,799 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Medical Diagnostics & Research company?
A good Marketable Securities depends on the Medical Diagnostics & Research industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Sai Life Sciences and its competitors. Sai Life Sciences's current Marketable Securities is ₹1,799 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Life Sciences stock overvalued right now?
Sai Life Sciences (NSE:SAILIFE) has a current Marketable Securities of ₹1,799 Mil. The current Marketable Securities is ₹1,799 Mil. Sai Life Sciences' overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Sai Life Sciences (NSE:SAILIFE), the current Marketable Securities is ₹1,799 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sai Life Sciences Business Description

Other Exchanges 544306:India
Address Gachibowli Miyapur Road, L4- 01 & 02, SLN Terminus Survey, Survey no. 133, Gachibowli, Hyderabad, TG, IND, 500032
Sai Life Sciences Ltd is an innovator-focused, contract research, development, and manufacturing organization. It provides end-to-end services across the drug discovery, development, and manufacturing value chain, for small molecule new chemical entities (NCE), to pharmaceutical innovator companies and biotechnology firms. It possesses both; discovery/contract research (CRO) and chemistry, manufacturing, and control (CMC)/contract development and manufacturing organization (CDMO) capabilities. The company has only one reportable segment: contract research, development, and manufacturing. Geographically it operates in India as well as Outside India.
18GF Score

Get the complete analysis for NSE:SAILIFE

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,315.10
Price